Fuller & Thaler reports 5.1% stake in Indivior

Indivior Pharmaceuticals, Inc. disclosed that Fuller & Thaler Asset Management, Inc., a California-based investment adviser, beneficially owns 6,371,533.70 shares of its common stock, representing 5.10% of the class as of 12/31/2025.

Accepted by SEC EDGAR 02/17/2026 - 01:37 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. disclosed that Fuller & Thaler Asset Management, Inc., a California-based investment adviser, beneficially owns 6,371,533.70 shares of its common stock, representing 5.10% of the class as of 12/31/2025.

Fuller & Thaler reports sole voting power over 6,193,613.70 shares and sole dispositive power over 6,371,533.70 shares, with no shared voting or dispositive power. The firm states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Indivior.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Fuller & Thaler hold in Indivior Pharmaceuticals (INDV)?

Fuller & Thaler Asset Management, Inc. reports beneficial ownership of 6,371,533.70 Indivior common shares, equal to 5.10% of the class. This reflects a significant institutional position above the 5% reporting threshold for Schedule 13G filings.

What voting power does Fuller & Thaler report over INDV shares?

Fuller & Thaler reports sole voting power over 6,193,613.70 shares of Indivior common stock and no shared voting power. This indicates the firm can vote or direct the vote for that number of shares under its discretionary authority.

What dispositive power does Fuller & Thaler have over Indivior (INDV) stock?

Fuller & Thaler reports sole dispositive power over 6,371,533.70 shares of Indivior common stock and no shared dispositive power. Dispositive power means the firm can decide whether and when to sell those shares for its advisory clients.

Why is Fuller & Thaler deemed the beneficial owner of INDV shares?

Fuller & Thaler is deemed beneficial owner because it acts as investment adviser for various clients holding Indivior shares. Under separate advisory arrangements, it directs investment decisions, while each underlying client retains the economic interest in dividends and sale proceeds.

Is Fuller & Thaler seeking to influence control of Indivior Pharmaceuticals?

Fuller & Thaler certifies the Indivior shares were acquired and are held in the ordinary course of business and not for changing or influencing control. The position is reported on Schedule 13G, typically used for passive or non‑control-oriented holdings.

What triggered this Indivior (INDV) Schedule 13G filing date?

The filing relates to a 12/31/2025 event date, when Fuller & Thaler’s beneficial ownership in Indivior common stock reached or exceeded 5%. Crossing that threshold requires a Schedule 13G or 13D to disclose the institutional holder’s stake and control intentions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Indivior Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

G4766E116

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G4766E116

1

Names of Reporting Persons

Fuller & Thaler Asset Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,193,613.70
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,371,533.70
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,371,533.70

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.10 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Indivior Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 10710 MIDLOTHIAN TURNPIKE, SUITE 125, NORTH CHESTERFIELD, VA, 23235
Item 2.
(a)	Name of person filing: Fuller & Thaler Asset Management, Inc.
(b)	Address or principal business office or, if none, residence: 411 Borel Avenue, Suite 300, San Mateo, CA 94402
(c)	Citizenship: California corporation
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: G4766E116
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6,371,533.70
(b)	Percent of class: 5.10%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 6,193,613.70
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6,371,533.70
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Fuller & Thaler Asset Management, Inc. is deemed to be the beneficial owner of the number of securities reflected in Items 5-9 and 11 of page two (2) of this Schedule 13G pursuant tos eparate arrangements whereby it acts as investment adviser to certain persons. Each person for whom Fuller & Thaler Asset Management, Inc. acts as investment adviser has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Fuller & Thaler Asset Management, Inc.

Signature:	/s/ Hanna Zanoni
Name/Title:	Chief Compliance Officer
Date:	02/17/2026